+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate



Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate



British Journal of Anaesthesia 94(3): 324-329



Plasma substitutes such as hydroxyethyl starch (HES) and various dextrans may compromise the haemostatic system, thereby causing potentially dangerous bleeding. Whilst several mechanisms have been advanced to explain the nature of the coagulopathy induced by this colloid, there has been comparably little interest in devising ways to optimize haemostasis after a relative colloid overdose. Real-time whole blood (WB) clot formation profiles were recorded using a thrombelastographic method employing activation with tissue factor. The coagulation tracings were transformed into dynamic velocity profiles of WB clot formation. WB from healthy individuals (n=20) was exposed to haemodilution of approximately 55% with isotonic saline, HES 200/0.5, HES 130/0.4, and dextran 70, respectively. Possible modalities for improvement of the induced coagulopathy were explored, in particular ex vivo addition of a fibrinogen concentrate. WB coagulation profiles changed significantly with decreased clot strength, and a compromised propagation phase of clot formation. The duration of the initiation phase of WB coagulation was unchanged. No statistical differences were detected amongst the HES solutions and dextran 70. However, dextran 70 returned a more suppressed clot development and strength compared with the HES solutions. Ex vivo haemostatic addition of washed platelets (75 x 10(9) litre(-1)) and factor VIII (0.6 IU ml(-1)) produced insignificant changes in clot initiation, propagation, and in the clot strength. In contrast, ex vivo addition of a fibrinogen concentrate (1 g litre(-1)) improved the coagulopathy induced by all of the three individual plasma expanders tested. Coagulopathy induced by haemodilution with either HES 200/0.5, HES 130/0.4, and dextran 70 may be improved by fibrinogen supplementation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012693100

Download citation: RISBibTeXText

PMID: 15608046

DOI: 10.1093/bja/aei052


Related references

Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery. Journal of Thrombosis and Haemostasis 10(8): 1696-1698, 2012

Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/- fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine 21: 74, 2013

A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thrombosis and Haemostasis 96(4): 446-453, 2006

Effects of fibrinogen concentrate after shock/resuscitation: a comparison between in vivo microvascular clot formation and thromboelastometry*. Critical Care Medicine 41(11): E301-E308, 2013

Albumin-induced coagulopathy is less severe and more effectively reversed with fibrinogen concentrate than is synthetic colloid-induced coagulopathy. Scandinavian Journal of Clinical and Laboratory Investigation 73(2): 161-169, 2013

The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesthesia and Analgesia 106(5): 1360-5 Table of Contents, 2008

Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. Journal of Thrombosis and Haemostasis 13(12): 2192-2201, 2015

Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis 103(1): 25-34, 2012

Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesthesia and Analgesia 102(4): 1194-1200, 2006

Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: A study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial. Anaesthesia Critical Care and Pain Medicine 35(4): 293-298, 2016

Clot formation and gelatin-based plasma substitutes. Lancet 347(9011): 1336, 1996

Thrombelastographic whole blood coagulation parameters demonstrate improved clot strength induced by tranexamic acid during cardiopulmonary bypass.. 2007

Incomplete transformation of plasma fibrinogen to fibrin. Fibrinogen content and streptokinase-induced intra-clot lysis susceptibility of des-AA or des-AABB fibrin clots formed at varying fibrinogen/fibrin ratios. Thrombosis Research 14(2-3): 507-512, 1979

Incomplete transformation of plasma fibrinogen to fibrin fibrinogen content and strepto kinase induced clot lysis susceptibility of des aa or des aabb fibrin clots formed at varying fibrinogen fibrin ratios. Thrombosis Research 14(2-3): 507-512, 1979

Reduced quality of clot formation with gelatin-based plasma substitutes. British Journal of Anaesthesia 80(2): 204-207, 1998